Leptotrichia shahii

Leptotrichia shahii is a species of anaerobic, gram-negative bacteria within the Fusobacteriota phylum. It was first described in 2004 from clinical specimens and is part of the complex oral microbiota. While often a commensal organism, it has been increasingly recognized for its potential role in various infectious diseases, particularly in immunocompromised individuals.

Description and taxonomy

The species was formally described in the International Journal of Systematic and Evolutionary Microbiology by a team led by Erling K. Eribe. It belongs to the genus Leptotrichia, which is classified under the family Leptotrichiaceae within the order Fusobacteriales. Morphologically, cells are typically long, non-spore-forming rods that may appear as filaments, a characteristic shared with related species like Leptotrichia buccalis. The taxonomic assignment was confirmed through 16S ribosomal RNA gene sequencing, which showed distinct phylogenetic divergence from other members of the genus, such as Leptotrichia trevisanii and Leptotrichia wadei. This genetic analysis placed it firmly within the broader context of the Fusobacteriota, a phylum known for its association with both human and animal hosts.

Habitat and isolation

Leptotrichia shahii is primarily isolated from the human oral cavity, where it resides as part of the normal microbial flora in sites like the gingival sulcus and dental plaque. It has also been recovered from other mucosal surfaces and clinical specimens beyond the oropharynx. The bacterium is strictly anaerobic, requiring specialized culture techniques such as the use of prereduced media in an anaerobic chamber for isolation. Significant recovery has been reported from samples associated with periodontal disease and from blood cultures of patients with bacteremia. Its presence has been documented in studies conducted at institutions like the Mayo Clinic and the Centers for Disease Control and Prevention, highlighting its clinical relevance.

Pathogenicity and clinical significance

While its pathogenic role is not fully defined, Leptotrichia shahii is implicated in opportunistic infections, especially in hosts with compromised immune systems. It has been identified as a causative agent in cases of bacteremia, often in patients with hematological malignancies or those undergoing chemotherapy. Associations have been reported with abscess formation, joint infections, and septicemia. The organism's ability to translocate from the oral mucosa into the bloodstream, a process potentially facilitated by mucosal barrier injury, is a key factor in its disease pathogenesis. Its clinical significance parallels that of other opportunistic pathogens within the Fusobacteriota, such as Fusobacterium nucleatum.

Genomics and molecular characteristics

The complete genome sequence of Leptotrichia shahii has provided insights into its metabolic capabilities and virulence potential. Genomic analysis reveals genes associated with adhesion to host tissues and anaerobic respiration. The GC-content of its DNA is consistent with other members of the genus. Molecular studies, including multilocus sequence typing, have helped delineate its population structure and evolutionary relationship to species like Leptotrichia goodfellowii. Research utilizing techniques like polymerase chain reaction and whole-genome sequencing has been instrumental in tracking its presence in complex clinical samples and understanding its role in polymicrobial infections.

Antimicrobial susceptibility

In vitro susceptibility testing indicates that Leptotrichia shahii is generally susceptible to several antimicrobial agents. Effective antibiotics typically include metronidazole, clindamycin, and carbapenems such as imipenem. It often shows resistance to aminoglycosides, which is expected for an anaerobic bacterium. Standardized testing methods from the Clinical and Laboratory Standards Institute are used to determine minimum inhibitory concentration values. Susceptibility profiles are crucial for guiding treatment, especially in serious infections like endocarditis or osteomyelitis, where targeted therapy is required. Ongoing surveillance by bodies like the World Health Organization monitors for emerging resistance patterns among anaerobic pathogens.

Category:Bacteria Category:Anaerobic bacteria